Waters Corp Receives FDA Clearance for Blood Cancer Diagnostic Tests
Waters gained FDA 510(k) clearance for two clinical flow cytometry tests for blood cancers, following a recent increase in full-year 2026 revenue guidance.
Waters Corporation recently obtained 510(k) clearance from the U.S. Food and Drug Administration to market two of its flow cytometry diagnostics, the BD OneFlow LST and BD OneFlow B-CLPD T1. Designed to assist medical personnel in detecting B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia, the tests delivered 96.3% sensitivity and 98.2% specificity in identifying the latter condition. The standardized setup decreases manual handling by approximately 95% compared to traditional liquid reagent cocktails.
The regulatory clearance allows the diagnostic tools to be commercially distributed across the United States. Preorders have opened, with a commercial release planned for spring 2027 through regional sales staff and online platforms. Management described the clearance as a major step toward expanding reliable cancer diagnostics, noting that an estimated 79,320 individuals in the United States are projected to be diagnosed with non-Hodgkin lymphoma in 2026, including 22,760 cases of chronic lymphocytic leukemia. Shares of Waters rose 2.9% the day after the regulatory announcement, bringing its market capitalization to $46.83 billion.
The regulatory news comes after the company lifted its full-year 2026 earnings outlook, boosting expected revenue by US$43 million at the midpoint. Waters has seen strong operational performance in key product lines, as chemistry columns grew 10% in the second quarter of 2026, while testing revenue related to GLP 1 treatments climbed by more than 40%. On November 09, 2026, the stock gained 4.2% to close at $476.70, hovering near the upper end of its 52-week trading range of $282.77 to $482.28.
Despite the commercial progress, market commentators hold differing views on the company's valuation. An analyst narrative on Simply Wall St suggested the shares were roughly 1% overvalued against a consensus fair value of $470.82, while noting potential risks from China business trends and integration synergies. GuruFocus reported a GF Value of $445.23, viewing the $476.70 price as about 7.1% overvalued while recording a GF Score of 96/100. GuruFocus also pointed out that corporate insiders engaged in net sales of $1.0 million over the trailing 12 months, consisting of $0.5 million in purchases against $1.4 million in sales.